S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Stock market today: World stocks mixed as Wall St inches toward bull market
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Stock market today: World stocks mixed as Wall St inches toward bull market
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Stock market today: World stocks mixed as Wall St inches toward bull market
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
The $193 Billion US-China War You Don't Know About (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
3 Reasons The Wayfair Rally Is Way Overdone
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Stock market today: World stocks mixed as Wall St inches toward bull market
146 Pounds of Graphite Needed for Each EV (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
NASDAQ:TPST

Tempest Therapeutics (TPST) Stock Forecast, Price & News

$1.47
+0.01 (+0.68%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.38
$1.55
50-Day Range
$1.44
$3.76
52-Week Range
$1.06
$4.21
Volume
245,393 shs
Average Volume
66,969 shs
Market Capitalization
$17.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Tempest Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,147.2% Upside
$18.33 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Tempest Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.19) to ($2.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

683rd out of 982 stocks

Pharmaceutical Preparations Industry

335th out of 480 stocks


TPST stock logo

About Tempest Therapeutics (NASDAQ:TPST) Stock

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.

Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Stock News Headlines

Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Analyst Ratings for Tempest Therapeutics
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
8-K: Tempest Therapeutics, Inc.
See More Headlines

TPST Price History

TPST Company Calendar

Last Earnings
3/22/2023
Today
6/07/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TPST
Fax
N/A
Employees
14
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+580.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-35,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.72 per share

Miscellaneous

Free Float
10,990,000
Market Cap
$17.04 million
Optionable
Not Optionable
Beta
0.91

Social Links


Key Executives

  • Stephen R. Brady
    Chief Executive Officer & Director
  • Thomas W. DubenskyThomas W. Dubensky
    President & Director
  • Nicholas Maestas
    Secretary, Vice President-Finance & Strategy
  • Sam Whiting
    Chief Medical Officer & Executive Vice President
  • Darrin Bomba
    Vice President-Clinical Operations













TPST Stock - Frequently Asked Questions

Should I buy or sell Tempest Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares.
View TPST analyst ratings
or view top-rated stocks.

What is Tempest Therapeutics' stock price forecast for 2023?

4 brokers have issued 1 year target prices for Tempest Therapeutics' shares. Their TPST share price forecasts range from $6.00 to $35.00. On average, they predict the company's stock price to reach $18.33 in the next year. This suggests a possible upside of 1,147.2% from the stock's current price.
View analysts price targets for TPST
or view top-rated stocks among Wall Street analysts.

How have TPST shares performed in 2023?

Tempest Therapeutics' stock was trading at $1.15 at the start of the year. Since then, TPST stock has increased by 27.8% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

Are investors shorting Tempest Therapeutics?

Tempest Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 77,900 shares, an increase of 144.2% from the April 30th total of 31,900 shares. Based on an average daily trading volume, of 238,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.5% of the company's stock are sold short.
View Tempest Therapeutics' Short Interest
.

When is Tempest Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our TPST earnings forecast
.

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its earnings results on Wednesday, March, 22nd. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09.

When did Tempest Therapeutics' stock split?

Tempest Therapeutics shares reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Tempest Therapeutics' stock symbol?

Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST."

Who are Tempest Therapeutics' major shareholders?

Tempest Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.10%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode.
View institutional ownership trends
.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tempest Therapeutics' stock price today?

One share of TPST stock can currently be purchased for approximately $1.47.

How much money does Tempest Therapeutics make?

Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $17.04 million. The company earns $-35,710,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

How can I contact Tempest Therapeutics?

Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at 415-798-8589 or via email at stephanie@sternir.com.

This page (NASDAQ:TPST) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -